The monoclonal antibody A6, isolated during a study on the natural immunoresponse of BALB/c mice against leukemia cells (4), reacts with the envelope glycoproteins gp70 of the MuLV and with the cell surface of the SL2 AKR leukemia. In the present paper, we describe the in vivo immunotherapeutic effect exerted by the A6 monoclonal antibody on the growth of the transplanted leukemia SL2. The greater therapeutic effect observed when the A6 was used with exogenous complement cooperation suggests that the immunotherapeutic activity is mediated by C'-dependent cytotoxicity.
Get full access to this article
View all access options for this article.
References
1.
BernsteinI.D., TarnM.R., NowinskiR.C.: Mouse Leukemia: Therapy with monoclonal antibodies against a thymus differentiation antigen.Science, 207: 68–71, 1980.
2.
BoiocchiM., PierottiM.A., MénardS., MiottiS., ColnaghiM.I.: Natural antilymphoma antibodies in C3Hf mice serum: Lack of identity with autoimmune and anti murine leukemia virus antibodies.Tumori, 65: 435–446, 1979.
3.
CinaderB., DubinskiS., WardlawA.C.: Distribution, inheritance, and properties of an antigen.MuB1, and its relation to hemolytic complement. J. Exp. Med., 120: 897–924, 1964.
4.
ColnaghiM.I., MénardS., TagliabueE., Della TorreG.: Heterogeneity of the natural humoral antitumor immunoresponse in mice as shown by monoclonal antibodies.J. Immunol., 128: 2757–2762, 1982.
5.
FishD.C., GildenR.V., BareR.M., TrimmerR.M., HuebnerR.J.: Prevention of spontaneous leukemia in AKR mice by passive immunization and type specificity of this protection.J. Natl. Cancer Inst., 62: 943–945, 1979.
6.
GreenwoodR.C., HunterW.M., GloverJ.S.: The preparation of 131I-labeled human growth hormone with high specific activity.Biochem. J., 39: 114–123, 1963.
7.
HuebnerR.J., GildenR.V., LaneW.T., ToniT., TrimmerR.V., HillP.R.: Suppression of murine type-C RNA virogenes by type-specific oncornavirus vaccines: Prospect for prevention of cancer.Proc. Natl. Acad. Sci. USA, 73: 620–624, 1976.
8.
IhleJ.M., LeeJ.C., HannaM.G.Jr.: Characterization of natural antibodies in mice to endogenous leukemia virus. In: « The Biology of Radiation Carcinogenesis », YuhasJ.M., TennantR.W., and ReganJ.D. (Eds.), pp. 261–273, Raven Press, New York1976.
9.
IhleJ.H., HannaM.G.Jr.: Natural immunity to endogenous oncornaviruses in mice. In: « Con-temporary Topics in Immunobiology », vol. 6, HannaM.G.Jr., RappR.F. (Eds.), pp. 169–191, Plenum Press, New York, London, 1977.
10.
JohnsonR.J., PasternakG.R., ShinP.J.: Preparation and therapeutic potential of rabbit antisera with « directed » specificities for mouse leukemias.Ann. N.Y. Acad. Sci., 277: 647, 1976.
11.
KawashimaR., IkedaH., StockertE., TakahashiT., OldL.J.: Age-related changes in cell surface antigens of preleukemic AKR thymocytes.J. Exp. Med., 144: 193–208, 1976.
12.
KesslerS.W.: Rapid isolation of antigens from cells with a staphylococcal protein A antibody absorbent: Parameters of the interaction of antibody-antigen complexes with protein A.J. Immunol., 115: 1617–1624, 1975.
13.
KirckM.E., HammerlingU.: Immunotherapy of murine leukemias by monoclonal antibody.I. Effect of passively administered antibody on growth of transplanted tumor cells. J. Immunol., 127: 805–810, 1981.
14.
LedbetterJ.A., NowinskiR.C., EmeryS.R.: Viral proteins expressed on the surface of murine leukemia cells.J. Virol., 22: 65–73, 1977.
15.
LostromM.E., StoneM.R., TarnM.R., BurnetteW.N., PinterA., NowinskiR.C.: Monoclonal antibodies against murine leukemia viruses.Identification of six antigenic determinants on the p15(E) and gp70 envelope proteins. Virology, 98: 336–350, 1979.
16.
ManciniG., CarbonaraA.O., HeremansJ.F.: Immunochemical quantitation of antigens by single radial immunodiffusion.Immunochemistry, 2: 235–254, 1965.
17.
NowinskiR.C., DoyleT.: Cellular changes in the thymuses of preleukemic AKR mice; Correlation with changes in the expression of murine leukemia viruses.Cell, 12: 341–353, 1977.
18.
NowinskiR.C., HaysE.F., DoyleT., LinkhartS., ModeirosE., PickeringR.: Oncornaviruses produced by murine leukemia cells in culture.Virology, 81: 363–370, 1977.
19.
PetersR.L., SassB., StephensonJ.R., Al-GhazzouliI.K., HinoS., DonahoeR.M., KendeM., AaronsonS.A., KelloffG.F.: Immunoprevention of X-ray-induced leukemias in the C57BL mouse.Proc. Natl. Natl. Cancer Inst., 55: 945–949, 1976.
20.
PierottiM.A., ColnaghiM.I.: Natural antibodies directed against murine lymphosarcoma cells.J. Natl. Cancer Inst., 55: 945–949, 1976.
21.
RoweW.P.: Genetic factors in the natural history of murine leukemia virus infection.G.H.A. Clowes Memorial Lecture. Cancer Res., 136: 1286–1301, 1973.
22.
SchwartzH., FischingerP.J., IhleJ.N., ThielHJ., WeilandF., BolognesiD.P., SchäferW.: Properties of mouse leukemia viruses.XVI. Suppression of spontaneous fatal leukemias in AKR mice by treatment with broadly reacting antibody against the viral glycoprotein gp71. Virology, 93: 159–174, 1979.
23.
ShinH.S., EconomonJ.S., PasternakG.R., JohnsonR.J., HaydenM.L.: Antibody-mediated suppression of grafted lymphomas.IV. Influence of time of tumor residency in vivo and tumor size upon the effectiveness of suppression by syngeneic antibody. J. Exp. Med., 144: 1274–1283, 1976.
24.
TarnR.M., GreenW.R., NowinskiR.C.: Cytotoxic activities of monoclonal antibodies against the envelope proteins of murine leukemia virus.Cancer Res., 40: 3850–3853, 1980.
25.
YamamotoN., HinumaY.: Antigens in an adult T-cell leukemia virus-producer cell line: Reactivity with human serum antibodies.Int. J. Cancer, 30: 289–293, 1982.
